» Articles » PMID: 31183519

Improved Peptide-MHC Class II Interaction Prediction Through Integration of Eluted Ligand and Peptide Affinity Data

Overview
Journal Immunogenetics
Date 2019 Jun 12
PMID 31183519
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Major histocompatibility complex (MHC) class II antigen presentation is a key component in eliciting a CD4+ T cell response. Precise prediction of peptide-MHC (pMHC) interactions has thus become a cornerstone in defining epitope candidates for rational vaccine design. Current pMHC prediction tools have, so far, primarily focused on inference from in vitro binding affinity. In the current study, we collate a large set of MHC class II eluted ligands generated by mass spectrometry to guide the prediction of MHC class II antigen presentation. We demonstrate that models developed on eluted ligands outperform those developed on pMHC binding affinity data. The predictive performance can be further enhanced by combining the eluted ligand and pMHC affinity data in a single prediction model. Furthermore, by including ligand data, the peptide length preference of MHC class II can be accurately learned by the prediction model. Finally, we demonstrate that our model significantly outperforms the current state-of-the-art prediction method, NetMHCIIpan, on an external dataset of eluted ligands and appears superior in identifying CD4+ T cell epitopes.

Citing Articles

3D genome contributes to MHC-II neoantigen prediction.

Feng M, Liu L, Su K, Su X, Meng L, Guo Z BMC Genomics. 2024; 25(Suppl 2):889.

PMID: 39327585 PMC: 11425871. DOI: 10.1186/s12864-024-10687-3.


Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy.

Eskandari A, Leow T, Rahman M, Oslan S Mol Biotechnol. 2024; .

PMID: 38625508 DOI: 10.1007/s12033-024-01144-3.


RPEMHC: improved prediction of MHC-peptide binding affinity by a deep learning approach based on residue-residue pair encoding.

Wang X, Wu T, Jiang Y, Chen T, Pan D, Jin Z Bioinformatics. 2024; 40(1).

PMID: 38175759 PMC: 10796178. DOI: 10.1093/bioinformatics/btad785.


Therapeutic cancer vaccines: advancements, challenges, and prospects.

Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C Signal Transduct Target Ther. 2023; 8(1):450.

PMID: 38086815 PMC: 10716479. DOI: 10.1038/s41392-023-01674-3.


Does human homology reduce the potential immunogenicity of non-antibody scaffolds?.

De Groot A, Khan S, Mattei A, Lelias S, Martin W Front Immunol. 2023; 14:1215939.

PMID: 38022550 PMC: 10664710. DOI: 10.3389/fimmu.2023.1215939.


References
1.
Saini S, Rekers N, Hadrup S . Novel tools to assist neoepitope targeting in personalized cancer immunotherapy. Ann Oncol. 2017; 28(suppl_12):xii3-xii10. DOI: 10.1093/annonc/mdx544. View

2.
Andreatta M, Lund O, Nielsen M . Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach. Bioinformatics. 2012; 29(1):8-14. DOI: 10.1093/bioinformatics/bts621. View

3.
Wieczorek M, Abualrous E, Sticht J, Alvaro-Benito M, Stolzenberg S, Noe F . Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Front Immunol. 2017; 8:292. PMC: 5355494. DOI: 10.3389/fimmu.2017.00292. View

4.
Shugay M, Bagaev D, Zvyagin I, Vroomans R, Crawford J, Dolton G . VDJdb: a curated database of T-cell receptor sequences with known antigen specificity. Nucleic Acids Res. 2017; 46(D1):D419-D427. PMC: 5753233. DOI: 10.1093/nar/gkx760. View

5.
Andreatta M, Nielsen M . Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2015; 32(4):511-7. PMC: 6402319. DOI: 10.1093/bioinformatics/btv639. View